BioCryst Pharmaceuticals

BCRX · NASDAQ

$7.94−$0.13 (−1.61%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.07

Latest news

Press releaseOct 5, 7:00 AM ETGlobe Newswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
NewsAug 26, 8:01 AM ETAvi Kapoor
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Press releaseAug 25, 7:01 AM ETGlobe Newswire
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
Press releaseAug 5, 7:00 AM ETGlobe Newswire
BioCryst Reports Second Quarter 2026 Financial Results
Press releaseJun 29, 7:00 AM ETGlobe Newswire
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
Press releaseJun 12, 7:00 AM ETGlobe Newswire
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Press releaseMay 27, 7:00 AM ETGlobe Newswire
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
NewsMay 7, 1:46 PM ETAvi Kapoor
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
NewsMay 6, 9:28 AM ET
Full Transcript: BioCryst Pharma Q1 2026 Earnings Call
NewsMay 6, 7:15 AM ET
BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate
Press releaseMay 6, 7:00 AM ETGlobe Newswire
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 4, 7:10 AM ET
BioCryst And Neopharmed Gentili Expand Partnership With European Navenibart HAE License Delivering $70M Upfront And 18-30% Tiered Royalties
Press releaseMay 4, 7:00 AM ETGlobe Newswire
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
NewsFeb 26, 7:40 AM ET
BioCryst Pharma: Q4 Earnings Insights
NewsFeb 26, 7:38 AM ET
BioCryst Pharma Q4 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $163.284M Beat $151.326M Estimate
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
NewsJan 20, 1:21 PM ET
BioCryst Pharma Option Alert: Feb 20 $8 Calls Sweep (4) near the Ask: 3512 @ $0.15 vs 1439 OI; Earnings 2/23 Before Open [est] Ref=$6.595
Press releaseJan 7, 5:12 PM ETPRNewswire
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
NewsDec 12, 10:24 AM ETVandana Singh
BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug
Press releaseNov 12, 8:00 AM ETBusiness Wire
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
NewsNov 3, 9:14 AM ETErica Kollmann
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Press releaseOct 17, 3:20 PM ETBusiness Wire
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Press releaseOct 14, 7:00 AM ETBusiness Wire
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
NewsAug 21, 2:24 PM ETVandana Singh
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
NewsAug 1, 3:05 PM ET
Earnings Outlook For BioCryst Pharma
NewsMay 5, 5:29 PM ETVandana Singh
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
NewsMay 5, 12:28 PM ETAvi Kapoor
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
NewsMay 5, 8:07 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

BioCryst Reports Second Quarter 2026 Financial Results

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

Earnings Scheduled For May 6, 2026

Full Transcript: BioCryst Pharma Q1 2026 Earnings Call

BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst And Neopharmed Gentili Expand Partnership With European Navenibart HAE License Delivering $70M Upfront And 18-30% Tiered Royalties

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Pharma: Q4 Earnings Insights

BioCryst Pharma Q4 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $163.284M Beat $151.326M Estimate

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For February 26, 2026

BioCryst Pharma Option Alert: Feb 20 $8 Calls Sweep (4) near the Ask: 3512 @ $0.15 vs 1439 OI; Earnings 2/23 Before Open [est] Ref=$6.595

Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

Earnings Outlook For BioCryst Pharma

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

12 Health Care Stocks Moving In Monday's Pre-Market Session